Peptide Stack · Combination Concept
Why Specific Peptide Combinations Are Discussed
Each page explains what is in a combination, why those components are commonly paired, what evidence exists for the exact combination versus its individual components, and where separate administration may be preferable. This is not a dosing or protocol guide.
BPC-157 + TB-500
Soft-tissue repair and recovery research
A two-component pairing commonly discussed in soft-tissue repair and recovery research, combining BPC-157's preclinical tissue-repair and vascular research with TB-500's actin-binding, cell-migration research -- component-level evidence only, with no controlled trial of the exact pairing.
CJC-1295 without DAC + Ipamorelin
Dual-pathway growth-hormone-release research
A pairing of a GHRH-receptor-type signal with a ghrelin/GHS-receptor secretagogue signal, grounded in general dual-pathway GH-release physiology -- not a clinical trial of this exact commercial formulation.
Cagrilintide + Semaglutide
Complementary amylin + GLP-1 appetite/satiety/weight-regulation signaling
The only initial Combination Concept page with direct human exact-combination evidence: distinct amylin (Cagrilintide) and GLP-1 (Semaglutide) pathways studied together in a clinical development program -- though the ERP research vial is not the same product as the studied pharmaceutical formulation.
GLOW
Repair, extracellular-matrix, and skin-remodeling research
A three-component pairing that builds on BPC-157 and TB-500's repair-research framing and adds GHK-Cu to introduce a copper-peptide, collagen, and extracellular-matrix research arm -- component-level evidence only, with no controlled trial of the exact three-component pairing.
KLOW
Repair, remodeling, and inflammatory-signaling research
A four-component pairing that extends GLOW by adding KPV, introducing an additional inflammatory- and mucosal-signaling research arm alongside the repair, cell-migration, and extracellular-matrix arms already described for GLOW -- component-level evidence only, with no controlled trial of the exact four-component pairing.
Retatrutide + Cagrilintide
GLP-1/GIP/glucagon receptor agonism + amylin signaling
A pairing of Retatrutide's investigational triple-receptor metabolic signaling with Cagrilintide's amylin-receptor satiety pathway -- no exact-combination human trial exists, and CagriSema evidence for a different pairing must not be extrapolated to this one.
Semax + Selank
Cognitive, attention, and stress-modulation research
A pairing of Semax's cognitive/attention research framing with Selank's anxiolytic/stress-modulation research framing -- a community-described pairing of complementary research themes, not a demonstrated pharmacodynamic correction of one by the other.
Tesamorelin + Ipamorelin
GHRH analogue + GH-secretagogue dual-pathway research
A pairing of Tesamorelin, an FDA-approved GHRH analogue for a narrow indication, with Ipamorelin, a receptor-distinct GH-secretagogue -- grounded in general dual-pathway GH-release physiology, not a trial of this exact formulation, and not a general weight-loss or anti-aging combination.